Lung Cancer

A panel of thought leaders in the management of NSCLC review best practices for monitoring patients and making treatment decisions after adjuvant osimertinib.

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.

Savolitinib has been granted a conditional approval in China for use in patients with non–small cell lung cancer with MET exon 14 skipping alterations who experienced disease progression after previous systemic therapy or are unable to receive chemotherapy.

Three-quarters of all cases of lung adenocarcinoma, the most common type of non–small cell lung cancer, are defined by oncogenic driver events involving receptor tyrosine kinase–orchestrated cellular signaling pathways.

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Experts in lung cancer discuss advances with targeted therapies in non–small cell lung cancer, highlighting the latest and most pivotal data in the thoracic space and how the data apply to clinical practice.

Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.

David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer

The addition of sintilimab to standard chemotherapy comprised of gemcitabine and platinum significantly improved progression-free survival with acceptable safety in previously untreated patients with advanced or metastatic squamous non–small cell lung cancer.

A panel of key opinion leaders in lung cancer considers the clinical implications of the ADAURA trial of adjuvant osimertinib and discuss how results may affect the treatment landscape in early stage NSCLC.

Key opinion leader in lung cancer Solange Peters, MD, PhD, reviews safety and efficacy results from the ADAURA trial of adjuvant osimertinib in patients with stage IB-IIIA EGFR-mutated NSCLC following surgical resection.

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in the realm of non–small cell lung cancer.

The potential role for antibody-drug conjugates for treating patients with non–small cell lung cancer continues to evolve as new data challenge investigators to reexamine their approaches.

Christian Grohé, MD, comments on results of clinical trials studying EGFR-TKI combination regimens in NSCLC and highlights the need for composite end points that include quality of life and disease control.

Expert panelists share insights on the results of the LUNG ART trial of postoperative radiotherapy in patients with resected stage IIIA-N2 disease and emphasize the risk for cardiac and pulmonary toxicity.

Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.

Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

In a final overall survival analysis of the J-ALEX study, patients with non-small cell lung cancer receiving alectinib failed to achieve better results than patients receiving crizotinib.

Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.

Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.